Bard, J&J face another vaginal mesh lawsuit; Komen foundation accused of exaggerating mammogram benefits;

 @FierceMedDev: Globus scales back its IPO pricing, now trading under GMED. More | Follow @FierceMedDev

 @MarkHFierce: Thoratec reported a Q2 loss but is banking on continued sales growth to carry the year. More | Follow @MarkHFierce

 @DamianFierce: Study: U.S. access to new devices no slower than EU's. More | Follow @DamianFierce

> C. R. Bard ($BCR) and Johnson & Johnson ($JNJ) are facing more lawsuits over the Gynecare transvaginal mesh, with a Florida plaintiff claiming significant injuries as result of the embattled implant. News

> In the British Medical Journal, researchers are accusing the Susan G. Komen for the Cure of vastly overstating the benefits of mammography, while almost entirely ignoring the procedure's risks. More

> The Medical College of Wisconsin is conducting a clinical study of InTone, an FDA-cleared device to treat female urinary incontinence. Release

> Intelligent Ultrasound, a diagnostics firm spun-out from Oxford University, signed on to develop Dx software for the U.K.'s National Health Service, expecting to save the agency $62 million per year. Article

> Dental products maker Sirona ($SIRO) topped analysts estimates in its third quarter, reporting net income of $30.3 million, down from last year's $36.3 million. Item

Biotech News

 @FierceBiotech: Yesterday's most popular story: Analyst reads last rites after heart failure scuttles Bristol hepatitis C study. Story | Follow @FierceBiotech

 @JohnCFierce: Bankers tally torrid pace for biotech M&A as hungry suitors pounce. More | Follow @JohnCFierce

 @RyanMFierce: A record for GSK? Asks for FDA approval for targeted melanoma treatment roughly 3 years after hitting the clinic. More | Follow @RyanMFierce

> J&J's boost in Doxil supply benefits study of Endocyte/Merck drug. Article

> Biotech startup Atterocor grabs $16M A round for cancer compound. More

> H1 venture deals: Celladon moves up in the rankings. Update

> Burrill & Co. boosts latest life sciences fund to $505M. News

> GSK races to regulators for approvals of new skin cancer drugs. Article

Pharma News

 @FiercePharma: More on "how not to insider trade," with Bristol-Myers exec as exhibit A, from The Wall Street JournalMore | Follow @FiercePharma

> J&J acknowledges what everyone knows, it settled with DoJ. Story

> Johnson & Johnson releases some Doxil for trials. More

> Investors bite on Pfizer's Sandwich site. News

> GSK tries volume, goodwill, over margins in Africa. Article

> Bloomberg: India's Sun sizes up deal with Germany's Stada. Story

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.